Dobarganes-Barlow F, Otero-Cámara E, Romero-Vargas S, Pérez-Frías J, Negrete-Corona J

Language: Spanish
References: 9
Page: 228-232
PDF size: 232.55 Kb.

ABSTRACT

Backgound: Gonarthrosis is a degenerative condition that importantly limits an individual’s performance. Surgical treatment is used in patients with important functional limitation and severe pain. Knee arthroplasty is one of the surgeries with the best functional results in patients with this condition. However, its limitations include the risk of heavy bleeding and the resulting need for blood transfusion. The objective of this study was to assess the need for blood transfusion in patients undergoing knee arthroplasy in whom the cell saver was used postoperatively and find out the cost differences between the cell saver and standard blood transfusion. Methods: Retrospective, cross-sectional, retrolective trial including 300 records of patients who underwent knee arthroplasty at Hospital Ángeles Querétaro that included the use of the cell saver and allogeneic blood transfusion from October 2001 to June 2013. Results: Only 3 of the 246 operated knees required allogeneic blood transfusion. There were no complications/infections resulting from the use of the cell saver. Mean age of patients was 67.1 ± 9.78 years; females were predominant, as they were 141 (60.5%), compared to 92 (39.5%) males. The blood collected with the cell saver ranged from 150 to 1,225 ml with a mean of 318 ± 100.6 ml and was retransfused to each patient. Conclusions: Cell saver use in patients subjected to knee arthroplasty importantly decreases the need for allogeneic blood transfusion.

REFERENCES

1. Lotke PA, Faralli VF, Orenstein EM, Ecker ML: Blood loss after total knee replacement: effects of tourniquet release and continuous passive motion. J Bone Joint Surg Am. 1991; 73: 1037.

2. Bierbaum BE, Callaghan JJ, Galante JO, et al: An analysis of blood management in patients having a total hip or knee arthoraoplasty. J Bone and Joint Surg Am. 1999; 81: 2.

3. Zou S, Stramer S, Dodd R: Donor Testing and Risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfusion Med Rev. 2012; 26(2): 119-28.

4. Woolson S, Wall W: Autologos blood transfusion after total knee arthoraoplasty. A randomized, prospective study comparing predonated and postoperative salvage blood. J Arthoraop. 2003; 18(3): 2-10.

5. Noticewala MS, Nyce JD, Wang W, Geller JA, Macaulay W: Predicting need for allogeneic transfusion after total knee arthoraoplasty. J Arthoraop. 2012; 27(6).

6. Shander A, Hofmann A, Ozawa S, Theusinger O, Gombotz H, Spahn D: Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion. 2010; 50(4): 753-65.

7. Grosvenor D, Goyal V, Goodman S: Efficacy of postoperative blood salvage following total hip arthoraoplasty in patients with and without deposited autologous units. J Bone and Joint Surg Am. 2000; 82-A(7): 951-4.

8. Majkowski RS, Currie IC, Newman JH: Postoperative collection and reinfusion of autologous blood in total knee arthoraoplasty. Ann R Coll Surg Engl. 1991; 73: 381.

9. Heddle NM, Brox WT, Klama LN, Dickson LL, Levine MN: randomized trial of the efficacy of an autologous blood drainage and transfusion device in patients undergoing elective knee arthoraoplasty. Transfusion. 1992; 32: 742.